Tags : ASCO

Clinical Trials

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as

Shots: Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study, demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups, including patients with high-risk CLL Additionally, Janssen will present 7yrs. data from the RESONATE-2 study on PFS and […]Read More